Page last updated: 2024-12-07

cholest-5-ene-3 beta,26-diol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cholest-5-ene-3 beta,26-diol: isolated from human brain [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

26-hydroxycholesterol : An oxysterol that is cholesterol substituted at position 26 by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID99470
CHEMBL ID3217768
CHEBI ID17703
SCHEMBL ID159618
MeSH IDM0049975

Synonyms (22)

Synonym
CHEBI:17703 ,
cholest-5-ene-3beta,26-diol
26-hydroxycholesterol
27-hydroxy-cholesterol
cholest-5-en-3beta,26-diol
LMST01010057
26-hydroxy-cholesterol
26259-77-8
nsc 226105
cholest-5-ene-3,26-diol, (3beta)-
(25r,s)-26-hydroxycholesterol
CHEMBL3217768
SCHEMBL159618
FYHRJWMENCALJY-CCDZVGGQSA-N
cholest-5-ene-3,26-diol #
cholest-5-ene-3,26-diol,(3b)-
AKOS030228167
Q27102543
(3s,8s,9s,10r,13r,14s,17r)-17-((2r)-7-hydroxy-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-ol
cholest-5-ene-3 beta,26-diol
DTXSID101314679
CS-0444283
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
EC 3.1.1.1 (carboxylesterase) inhibitorAny EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that inhibits the action of carboxylesterase (EC 3.1.1.1 ).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
26-hydroxy steroidAny hydroxy steroid in which a hydroxy group is located at position 26.
oxysterolAn oxygenated derivative of cholesterol
3beta-hydroxy-Delta(5)-steroidAny 3beta-hydroxy-steroid that contains a double bond between positions 5 and 6.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (17)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Metabolism of steroids111135
Bile acid and bile salt metabolism3171
Synthesis of bile acids and bile salts2068
Synthesis of bile acids and bile salts via 27-hydroxycholesterol718
Biological oxidations150276
Phase I - Functionalization of compounds69175
Cytochrome P450 - arranged by substrate type30110
Endogenous sterols1838
Phase II - Conjugation of compounds73122
Cytosolic sulfonation of small molecules1747
Cholesterol metabolism with Bloch and Kandutsch-Russell pathways039
Disorders of bile acid synthesis and biliary transport1840
Cholesterol metabolism214
Cholesterol biosynthesis pathway in hepatocytes1137
Sterols biosynthesis pathway015

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (37.50)18.7374
1990's19 (47.50)18.2507
2000's5 (12.50)29.6817
2010's1 (2.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.43 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index4.19 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]